SLC35E4

Across TCGA pan-cancer cohorts, SLC35E4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC35E4 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC35E4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC35E4 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

LSCC, GBM, and PDAC are the cancer types where SLC35E4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.537	0.857	<.001	22	view →
GBM	OS	Median	All	0.560	0.255	.011	14	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	11	view →
LUAD	OS	Tertile	II,III,IV	0.942	0.495	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC35E4–LSCC (DFS)

Open the LSCC breakdown →